Schneyer Mark C. 4
4 · ACADIA PHARMACEUTICALS INC · Filed Mar 26, 2025
Insider Transaction Report
Form 4
Schneyer Mark C.
EVP, CHIEF FINANCIAL OFFICER
Transactions
- Exercise/Conversion
Restricted Stock Units
2025-03-25−6,178→ 18,536 total→ Common Stock (6,178 underlying) - Exercise/Conversion
Common Stock
2025-03-25+6,178→ 60,060 total - Award
Stock Option (Right to Buy)
2025-03-24+110,761→ 110,761 totalExercise: $17.23Exp: 2035-03-23→ Common Stock (110,761 underlying) - Sale
Common Stock
2025-03-26$17.05/sh−3,171$54,066→ 56,889 total - Award
Restricted Stock Units
2025-03-24+32,552→ 32,552 total→ Common Stock (32,552 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F2]The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
- [F3]25% of the shares subject to the Stock Option will vest and become exercisable on March 24, 2026. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
- [F4]The restricted stock units vest in four equal annual installments beginning March 24, 2026.
- [F5]The restricted stock units vest in four equal annual installments beginning March 25, 2025.